Oncolytics’ Reolysin in new trial
The Children’s Oncology Group, in collaboration with the National Institutes of Health, intends to conduct a Phase 1 clinical trial of Oncolytics Biotech’s (TSX:ONC; NASDAQ:ONCY) Reolysin drug in...
View ArticleSynthetic Biologics’ sniper approach to infectious diseases
Taking a page out of the oncology sector and its approach to targeting specific cancers with new biologics, Synthetic Biologics (NYSE MKT:SYN) is developing treatments for infectious diseases in much...
View ArticleGamida Cell shifts focus to NiCord stem cell product
Closely held Gamida Cell has shifted its focus to its second-generation stem cell product, NiCord, for the treatment of hematological malignancies and non-malignant hematological diseases in the wake...
View ArticleEnrollment in Athersys stroke trial nears completion
Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke...
View ArticleCiclofilin developing first drug for HCV/HIV-1 co-infection
Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity...
View Article
More Pages to Explore .....